Atrial fibrillation (AF) is the most common sustained arrhythmia associated with significant morbidity and mortality. The mechanisms underlying the pathogenesis of AF are poorly understood, although electrophysiological remodeling has been described as an important initiating step. There is growing evidence that oxidative stress is involved in the pathogenesis of AF. Many known triggers of oxidative stress, such as age, diabetes, smoking, and inflammation, are linked with an increased risk of arrhythmia. Numerous preclinical studies and clinical trials reported the importance of antioxidant therapy in the prevention of AF, using vitamins C and E, polyunsaturated fatty acids, statins, or nitric oxide donors. The aim of our work is to give a current overview and analysis of opportunities, challenges, and benefits of antioxidant therapy in AF.

• Keywords
• Antioxidants, Atrial fibrillation, Atrial remodeling, Gene therapy, Oxidative stress, Prevention,
• MeSH
• Action Potentials MeSH
• Anti-Arrhythmia Agents pharmacology   MeSH
• Antioxidants therapeutic use   MeSH
• Atrial Fibrillation drug therapy   genetics   metabolism   physiopathology   MeSH
• Genetic Therapy methods   MeSH
• Humans MeSH
• Oxidative Stress drug effects   genetics   MeSH
• Atrial Remodeling drug effects   MeSH
• Risk Factors MeSH
• Heart Rate drug effects   MeSH
• Heart Atria drug effects   metabolism   physiopathology   MeSH
• Animals MeSH
• Check Tag
• Humans MeSH
• Animals MeSH
• Publication type
• Journal Article MeSH
• Review MeSH
• Names of Substances
• Anti-Arrhythmia Agents MeSH
• Antioxidants MeSH